Back to News
Market Impact: 0.35
AstraZeneca's Enhertu, Klygefa Get Positive CHMP Opinions In EU
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
AstraZeneca said the European Medicines Agency's CHMP recommended approval of Enhertu in an additional early breast cancer setting and Alexion's Klygefa for adults with a generalized condition. The positive CHMP opinions could expand the companies' addressable treatment populations, subject to final European Commission approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
AZN0.68
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- ‘The nail that sticks out gets hammered first’: Elon Musk’s net worth falls $113 billion from Tesla and SpaceX drops
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Stock Selloff Eases After $3 Trillion Rout
- Tesla will stop making the Cybertruck in 2027